Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients.
about
Advances in treatment of brain metastases from primary non-small cell lung cancerPemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature reviewCritical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerEfficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis.Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis.Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model.Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Prognostic value of cancer antigen -125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model.Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
P2860
Q27022452-B4A9BD33-91BD-41BE-8C98-C10F72DAC227Q31121041-43458AC8-05C1-49E3-B066-8E7CD9612080Q33710152-25518ED8-B309-43A7-9B46-E8AD595B6F82Q34772704-E2A93885-AFB8-4DF2-9089-F0B0BB073781Q35962441-F97AA711-D7F3-48BD-8DE0-00CC768D695CQ36140948-F8FBDC84-29FE-4D2D-88EC-326E22B38347Q36684011-F6616FC5-5F05-453F-8026-5E5374EDC5C9Q47154229-40776FB0-2F08-4AE1-8A6B-EDDDDD49F61FQ52559905-ABCA0878-A826-45CF-8057-D7285BD5745CQ52606350-2C6868E1-CE0E-4B5A-A477-4CA7106D85B2Q55429658-CA82636E-7898-4EAC-9A98-CF9E7C1B84A5
P2860
Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy and EGFR tyrosine ...... ival analysis in 210 patients.
@en
Chemotherapy and EGFR tyrosine ...... ival analysis in 210 patients.
@nl
type
label
Chemotherapy and EGFR tyrosine ...... ival analysis in 210 patients.
@en
Chemotherapy and EGFR tyrosine ...... ival analysis in 210 patients.
@nl
prefLabel
Chemotherapy and EGFR tyrosine ...... ival analysis in 210 patients.
@en
Chemotherapy and EGFR tyrosine ...... ival analysis in 210 patients.
@nl
P2093
P2860
P356
P1476
Chemotherapy and EGFR tyrosine ...... ival analysis in 210 patients.
@en
P2093
Haifeng Yu
Haiyan Yang
Nengming Lin
Weimin Mao
Zhiyu Huang
P2860
P304
P356
10.2147/OTT.S52172
P407
P577
2013-12-04T00:00:00Z